Articles > Research

  1. Advancing a Treatment for Acute Myeloid Leukemia

    In April we featured a Q&A in this blog with LLS-funded researcher Anthony Letai, MD, PhD, of Dana-Farber Cancer Institute, who discussed in his work leading to clinical trials of a drug called venetoclax (Venclexta ®) for acute myeloid leukemia (AML). The drug was FDA approved in April for a high-risk form of chronic lymphocytic leukemia (CLL). AML is a deadly blood cancer that has seen no change in the standard of care in 40 years. More than 20,000 people a year are diagnosed with A...

    Read More
  1. Zebrafish: A New Way to Study Leukemia

    David Traver, Ph.D., a professor of Cellular and Molecular Medicine at the University of California, San Diego, is the recipient of an LLS Career Development Program (CDP) grant. Traver’s research laboratory is using the zebrafish as a model to study the biology of cancer. Most of his team’s studies are aimed at understanding how the hematolymphoid system arises in the zebrafish embryo from the first hematopoietic stem cells. The zebrafish system offers easy visualization of blood cel...

    Read More
  2. Cancer Researcher Runs Alaska Half Marathon to Raise Funds for Lifesaving Treatments

    Not only has Irene Ghobrial, M.D. dedicated her professional life to finding lifesaving treatments for cancer, but over the past few months she has dedicated her leisure time to training for a half marathon in Alaska, to raise funds for cancer research. Ghobrial has trained with The Leukemia & Lymphoma Society’s (LLS) Team In Training (TNT), the non-profit’s endurance training program. Ghobrial, a Dana-Farber Cancer Institute (DFCI) physician-scientist, has been closely affiliated ...

    Read More
  3. A Vaccine to Treat Mantle Cell Lymphoma?

    Ronald Levy, professor of medicine and former chief of the Division of Oncology at Stanford University School of Medicine, helped develop and test the first US Food and Drug Administration (FDA)-approved monoclonal antibody against cancer for the treatment of B-cell lymphoma. Rituximab is now a standard of treatment alone and also in combination with chemotherapy regimens. Levy is receiving LLS funding through the Translational Research Program for research into an immunotransplant...

    Read More
  1. VP Biden Addresses Researchers @ ASCO16

    Speaking from the heart, Vice President Joseph Biden addressed thousands of cancer researchers today in a packed hall at the American Society of Clinical Oncology (#ASCO16) annual meeting in Chicago, to tout his Cancer Moonshot initiative. The theme of this year’s #ASCO16 meeting, “Collective Wisdom – The Future of Patient-Centered Care and Research,” is perfectly aligned with the goals of the Moonshot, Biden told the rapt audience.

    Read More
  2. Precision Medicine and Immunotherapy @ ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting featured several significant oral scientific presentations on the blood cancers over the weekend here in Chicago. CPX-351: A session on hematological malignancies Saturday afternoon included a discussion of final data from the Phase 3 clinical trial of Celator’s drug CPX-351 (Vyxeos ®). LLS invested substantially in this study through our Therapy Acceleration Program (TAP). The study was in a small subset of elderly pati...

    Read More
  3. Putting Patients at the Center of Care at #ASCO16

    The American Society of Clinical Oncology (#ASCO16) annual meeting kicked off today as more than 30,000 researchers from around the world converged in Chicago to share their latest clinical findings on treatments and diagnostics for all cancers, and to exchange ideas about how to improve outcomes for cancer patients. Putting patients at the center of cancer care and research is this year’s theme at ASCO, something we at The Leukemia & Lymphoma Society (LLS) try to do every day. Sprin...

    Read More
  4. Finding New Approaches to Immunotherapy

    Helen Heslop, M.D., leads a team of scientists being funded through LLS’s Specialized Center of Research Program (SCOR). The project brings together researchers from different institutions to test a half dozen novel approaches to cancer immunotherapy – all of which harness the patient's own immune system to fight the cancer. Heslop, a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy, pioneered...

    Read More
  5. Significant Advance for Hodgkin Lymphoma Patients

    The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...

    Read More
  6. Panelists Discuss the AML Patient Experience

    What is AML? What research is underway? And what resources are available to patients? The Leukemia & Lymphoma Society recently joined up with Patient Power and the MDS Alliance to host an AML Awareness Day and answer those questions. The April 21 webcast was moderated by Carol Preston, host of Patient Power, an online portal offering cancer information for both patients and professionals. Preston is also a chronic lymphocytic leukemia (CLL) survivor. The panelists were Ellen Ritc...

    Read More